A
Avalo Therapeutics
Biotech & Life Sciences · Rockville, United States · Founded 2011 · IPO 2015
Discovers, develops and commercializes neuroscience drugs MoreLess
Cerecor Inc. is a biopharmaceutical company focused on developing innovative therapies for rare pediatric and orphan diseases. The company operates in the healthcare and biotechnology sectors, targeting unmet medical needs with a robust pipeline of forward-thinking ideas. Cerecor serves patients who suffer from rare conditions, often with limited treatment options, and aims to improve their quality of life through advanced scientific research and clinical trials. The business model revolves around the discovery, development, and commercialization of novel therapeutic solutions. Cerecor generates revenue through public offerings, strategic partnerships, and the eventual commercialization of its drug candidates. The company is listed on the Nasdaq under the ticker symbol CERC and actively engages in investor relations to secure funding for its ambitious projects.
Keywords: biopharmaceutical, rare diseases, pediatric, orphan diseases, innovative therapies, clinical trials, Nasdaq, healthcare, biotechnology, drug development.
Company overview
Avalo Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2011
- Headquarters
- Rockville, United States
- Employees
- 48
- Open positions
- None listed
- Dealroom signal
- 91.3
- Investment activity
- 2 companies · latest Mar 2024
- Capital deployed
- —
- Preferred round
- ACQUISITION
Valuation & funding
Avalo Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | May 2026 | $375M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Jun 2025 | $75M | — | Undisclosed | ↗ |
| PRIVATE PLACEMENT VCOther financing | Mar 2024 | $185M | — | OrbiMed · BVF Partners · Commodore Capital · Deep Track Capital | ↗ |
| POST IPO EQUITYOther financing | Feb 2023 | $15M | — | Undisclosed | ↗ |
| POST IPO DEBTDebt | Aug 2021 | $10M | — | Horizon Technology Finance Corporation | — |
| POST IPO EQUITYOther financing | Jan 2021 | Undisclosed | — | ||
| POST IPO EQUITYOther financing | Apr 2017 | Undisclosed | — | ||
| GRANTOther financing | Apr 2016 | National Institute on Drug Abuse (NIDA) | — | ||
| IPOOther financing | Oct 2015 | Undisclosed | — | ||
| SERIES BOther financing | Jul 2014 | MPM BioImpact · Apple Tree Partners · NEA | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $59K | 0% | −$93M | -158118.6% |
| 2025 | $59K | -86.6% | −$10M | -16949.2% |
| 2024 | $441K | -77.1% | −$10M | -2267.6% |
| 2023 | $1.9M | -89.3% | −$10M | -519.8% |
| 2022 | $18M | +260% | −$10M | -55.6% |
| 2021 | $5M | -28.6% | −$10M | -200% |
| 2020 | $7M | — | −$10M | -142.9% |
Growth signals
Avalo Therapeutics website traffic
Latest recorded traffic for Avalo Therapeutics is 2.9K monthly website visits, down 54.7% over the last three months. Avalo Therapeutics's team grew 2.1% over the past year.
Comparisons
Avalo Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
Avalo Therapeutics investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
Avalo Therapeutics's talent
Source: Dealroom Talent Intelligence.
Investors
13 investors on Avalo Therapeutics's cap table
Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.
Global footprint
Where Avalo Therapeutics has talent and traffic
In the news
Latest news about Avalo Therapeutics
Recent press, funding announcements, and product moves mentioning Avalo Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Avalo Therapeutics
An AI-synthesized read of the highest-engagement posts about Avalo Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Avalo Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.